This review discusses the diagnostic work-up and cardiotoxic risk of anthracyclines and trastuzumab, highlighting cardiotoxicity as a risk factor in multimodal breast cancer therapy.
What are the adverse cardiovascular effects and diagnostic work-up for cardiotoxicity induced by systemic anticancer treatments like anthracyclines and trastuzumab in cancer patients?
This review highlights the importance of monitoring and managing the cardiotoxic risks associated with common anticancer therapies like anthracyclines and trastuzumab, especially in breast cancer patients.
Innovative anticancer strategies have contributed to an improved survival of patients suffering from malignancies, and in some cases, have turned cancer into a chronic disease. Therefore, the early and particularly late onsets of adverse cardiovascular effects of systemic anticancer treatments are of increasing interest. Among a rapidly increasing variety of anticancer drugs, the anthracyclines and the monoclonal antibody, trastuzumab, are the agents with a well-known cardiotoxicity. The diagnostic work-up, the cardiotoxic risk of anthracyclines and trastuzumab, and additionally, cardiotoxicity as a risk factor of a multimodal therapeutic approach in breast cancer patients is discussed in this study.
Geiger et al. (Fri,) conducted a review in Cancer (including breast cancer). Anticancer therapy (anthracyclines and trastuzumab) was evaluated. This review discusses the diagnostic work-up and cardiotoxic risk of anthracyclines and trastuzumab, highlighting cardiotoxicity as a risk factor in multimodal breast cancer therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: